Basit öğe kaydını göster

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

dc.contributor.authorFradet, Yves
dc.contributor.authorMatsubara, Nobuaki
dc.contributor.authorFlechon, Aude
dc.contributor.authorGunduz, Seyda
dc.contributor.authorLoriot, Yohann
dc.contributor.authorRodriguez-Vida, Alejo
dc.contributor.authorMamtani, Ronac
dc.contributor.authorYu, Evan Y.
dc.contributor.authorNam, Kijoeng
dc.contributor.authorImai, Kentaro
dc.contributor.authorMoreno, Blanca Homet
dc.contributor.authorAlva, Ajjai
dc.contributor.authorPowles, Thomas
dc.contributor.authorCsoszi, Tibor
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorGeczi, Lajos
dc.contributor.authorCheng, Susanna Y-S
dc.contributor.authorOudard, Stephane
dc.contributor.authorVulsteke, Christof
dc.contributor.authorBarrera, Rafael Morales
dc.date.accessioned2021-12-10T12:02:23Z
dc.date.available2021-12-10T12:02:23Z
dc.date.issued2021
dc.identifier.citationPowles T., Csoszi T., ÖZGÜROĞLU M., Matsubara N., Geczi L., Cheng S. Y. , Fradet Y., Oudard S., Vulsteke C., Barrera R. M. , et al., "Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial", LANCET ONCOLOGY, cilt.22, sa.7, ss.931-945, 2021
dc.identifier.issn1470-2045
dc.identifier.otherav_a4c08411-340b-499b-8c96-4f18a547eab6
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/173131
dc.identifier.urihttps://doi.org/10.1016/s1470-2045(21)00152-2
dc.description.abstractBackground PD-1 and PD-L1 inhibitors are active in metastatic urothelial carcinoma, but positive randomised data supporting their use as a first-line treatment are lacking. In this study we assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemotherapy for patients with previously untreated advanced urothelial carcinoma.
dc.language.isoeng
dc.subjectOnkoloji
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOncology
dc.subjectHealth Sciences
dc.titlePembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
dc.typeMakale
dc.relation.journalLANCET ONCOLOGY
dc.contributor.departmentUniversity Of London , ,
dc.identifier.volume22
dc.identifier.issue7
dc.identifier.startpage931
dc.identifier.endpage945
dc.contributor.firstauthorID2694661


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster